©istock.com/Andrea Obzerova
Interdisciplinary CompetenceMolecular Diagnostics
Know how in the analysis of genetic material.
For the benefit of patients.

IllnessBreast cancer / therapy with PARP inhibitors


Short information

2 single gene sequence analyses (BRCA1, BRCA2 genes) because of breast cancer in order to decide on the suitability of PARP-inhibitor therapy

Number of genes
2 Accredited laboratory test
Examined sequence length
15,9 kb (Core-/Core-canditate-Genes)
- (Extended panel: incl. additional genes)
Analysis Duration
on request
  • EDTA-anticoagulated blood (3-5 ml)
  • Gewebeprobe
Diagnostic indications




Gene panel

Selected genes

NameExon Length (bp)OMIM-GHeredity
BRCA15592AD, Mult
BRCA210257AD, Mult

Informations about the disease

Clinical Comment

Mutations in the BRCA1/2 genes are associated with an increased risk of familial breast or ovarian cancer, but also with a better response to therapy in breast cancer patients. The randomized Phase 3 study OlympiAD evaluated the efficacy and safety of olaparib monotherapy versus chemotherapy of choice in patients with metastatic breast cancer and germline mutations in the BRCA1 or BRCA2 genes. Progression-free survival was increased from 4.2 months (chemotherapy) to 7 months (olaparib) (2). The PARP inhibitor olaparib is approved for the treatment of advanced or metastatic HER2-negative BRCA mutant breast cancer that has previously responded sensitively to platinum-based chemotherapy (1).

References: (1) https://www.dgho.de/aktuelles/news/newsarchiv/2019/olaparib-beim-brcamut-mammakarzinom

(2) https://www.nejm.org/doi/full/10.1056/nejmoa1706450


  • Alias: Mamma-Ca (Behandlung mit PARP-Inhibitoren)
  • Alias: Mamma-Karzinom (BRCA1, BRCA2); Therapie
  • Alias: Olaparib-Therapie
  • Breast cancer (BRCA1, BRCA2) - Olaparib therapy
Heredity, heredity patterns etc.
  • AD
  • Mult
  • No OMIM-Ps linked
ICD10 Code

Bioinformatics and clinical interpretation

No text defined